These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38704478)

  • 1. Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
    Santagata S; Rea G; Bello AM; Capiluongo A; Napolitano M; Desicato S; Fragale A; D'Alterio C; Trotta AM; Ieranò C; Portella L; Persico F; Di Napoli M; Di Maro S; Feroce F; Azzaro R; Gabriele L; Longo N; Pignata S; Perdonà S; Scala S
    Br J Cancer; 2024 Jun; 130(12):2016-2026. PubMed ID: 38704478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.
    Santagata S; Napolitano M; D'Alterio C; Desicato S; Maro SD; Marinelli L; Fragale A; Buoncervello M; Persico F; Gabriele L; Novellino E; Longo N; Pignata S; Perdonà S; Scala S
    Oncotarget; 2017 Sep; 8(44):77110-77120. PubMed ID: 29100374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Neuropilin-1 Suppresses the Stability of CD4
    Gao YL; Wang CX; Wang ZY; Li WJ; Liu YC; Shou ST; Chai YF
    Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33139385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
    Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
    BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
    D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
    J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of neuropilin-1 in the stability of CD4
    Gao Y; Zhang X; Wang Z; Qiu Y; Liu Y; Shou S; Chai Y
    Immun Inflamm Dis; 2022 Feb; 10(2):143-154. PubMed ID: 34758202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.
    McClymont SA; Putnam AL; Lee MR; Esensten JH; Liu W; Hulme MA; Hoffmüller U; Baron U; Olek S; Bluestone JA; Brusko TM
    J Immunol; 2011 Apr; 186(7):3918-26. PubMed ID: 21368230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
    Cesana GC; DeRaffele G; Cohen S; Moroziewicz D; Mitcham J; Stoutenburg J; Cheung K; Hesdorffer C; Kim-Schulze S; Kaufman HL
    J Clin Oncol; 2006 Mar; 24(7):1169-77. PubMed ID: 16505437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs.
    Elkord E; Sharma S; Burt DJ; Hawkins RE
    Clin Immunol; 2011 Sep; 140(3):218-22. PubMed ID: 21570917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of semaphorin-3A on the cellular stability of CD4
    Gao Y; Li L; Liu Y; Li W; Wang Z; Shou S; Chai Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Dec; 32(12):1454-1460. PubMed ID: 33541497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.
    Liotta F; Gacci M; Frosali F; Querci V; Vittori G; Lapini A; Santarlasci V; Serni S; Cosmi L; Maggi L; Angeli R; Mazzinghi B; Romagnani P; Maggi E; Carini M; Romagnani S; Annunziato F
    BJU Int; 2011 May; 107(9):1500-6. PubMed ID: 20735382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased suppression of CD8
    Giri PS; Dwivedi M; Begum R
    Exp Dermatol; 2020 Aug; 29(8):759-775. PubMed ID: 32682346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expressions of PD-L1 and CTLA-4 by induced CD4
    Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
    Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma.
    Ning H; Shao QQ; Ding KJ; Gao DX; Lu QL; Cao QW; Niu ZH; Fu Q; Zhang CH; Qu X; Lü JJ
    Chin Med J (Engl); 2012 Jun; 125(12):2120-5. PubMed ID: 22884140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
    Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
    PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint.
    Müller M; Herrath J; Malmström V
    Clin Exp Immunol; 2015 Oct; 182(1):90-100. PubMed ID: 26076982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
    Siddiqui SA; Frigola X; Bonne-Annee S; Mercader M; Kuntz SM; Krambeck AE; Sengupta S; Dong H; Cheville JC; Lohse CM; Krco CJ; Webster WS; Leibovich BC; Blute ML; Knutson KL; Kwon ED
    Clin Cancer Res; 2007 Apr; 13(7):2075-81. PubMed ID: 17404089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of tumour-infiltrating FOXP3+ lymphocytes correlates with immature tumour angiogenesis in renal cell carcinomas.
    Zhan HL; Gao X; Zhou XF; Pu XY; Wang DJ
    Asian Pac J Cancer Prev; 2012; 13(3):867-72. PubMed ID: 22631663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity.
    Ferreira RC; Simons HZ; Thompson WS; Rainbow DB; Yang X; Cutler AJ; Oliveira J; Castro Dopico X; Smyth DJ; Savinykh N; Mashar M; Vyse TJ; Dunger DB; Baxendale H; Chandra A; Wallace C; Todd JA; Wicker LS; Pekalski ML
    J Autoimmun; 2017 Nov; 84():75-86. PubMed ID: 28747257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.